Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13290565 | 1.00 | CHRNA7 (0.42) | CHRNA7SIGMAR1CYP2D6KDM4EALDH1A1 | |
| SCHEMBL1093168 | 1.00 | — | — | |
| SCHEMBL104677 | 1.00 | — | — | |
| SCHEMBL24435951 | 0.96 | CHRNA7 (0.40) | CHRNA7SIGMAR1CYP2D6KDM4EALDH1A1 | |
| SCHEMBL13290564 | 0.96 | CHRNA7 (0.40) | CHRNA7SIGMAR1CYP2D6KDM4EALDH1A1 | |
| SCHEMBL840810 | 0.96 | CHRNA7 (0.40) | CHRNA7SIGMAR1CYP2D6KDM4EALDH1A1 | |
| SCHEMBL4911003 | 0.92 | — | — | |
| SCHEMBL24496310 | 0.92 | CHRNA7 (0.42) | CHRNA7SIGMAR1CYP2D6KDM4EALDH1A1 | |
| SCHEMBL57304 | 0.92 | — | — | |
| SCHEMBL840412 | 0.89 | CHRNA7 (0.41) | CHRNA7SIGMAR1CYP2D6KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720172-A1 | SIDE-CHAIN FUNCTIONALIZED POLYNORBORNENES AS IONOMERS AND AS MEMBRANE MATERIALS FOR ALKALINE ELECTROLYSIS OF WATER, AND FUEL CELL | Forschungszentrum Jülich GmbH (DE) | 2026-04-08 | — | — | EP | disclosed |
| WO-2025242796-A1 | HYDROGENATED SIDE-CHAIN FUNCTIONALIZED POLYNORBORNENE-ANION EXCHANGE POLYMERS AS MEMBRANE MATERIALS FOR ALKALINE WATER ELECTROLYSIS AND FUEL CELLS | Forschungszentrum Jülich GmbH (DE) | 2025-11-27 | — | — | WO | disclosed |
| WO-2024245731-A1 | SIDE-CHAIN FUNCTIONALIZED POLYNORBORNENES AS IONOMERS AND AS MEMBRANE MATERIALS FOR ALKALINE ELECTROLYSIS OF WATER, AND FUEL CELL | Forschungszentrum Jülich GmbH (DE) | 2024-12-05 | — | — | WO | disclosed |
| US-11897874-B2 | Compounds and methods for modulating Interleukin-2-inducible T-cell kinase | CORVUS PHARMACEUTICALS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-11897874-B2 | Compounds and methods for modulating Interleukin-2-inducible T-cell kinase | CORVUS PHARMACEUTICALS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230212549-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2023-07-06 | — | — | US | disclosed |
| WO-2022011205-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-01-13 | — | — | WO | disclosed |
| WO-2022011204-A1 | SMALL MOLECULE ANDROGEN RECEPTOR PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-01-13 | — | — | WO | disclosed |
| WO-2021231927-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-11-18 | — | — | WO | disclosed |
| US-20120142687-A1 | INDOLECARBOXYLIC ACID DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | KUGIMIYA AKIRA (JP) | 2012-06-07 | — | — | US | disclosed |
| US-8153793-B2 | Sulfonamide derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-8143285-B2 | Indolecarboxylic acid derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-03-27 | — | — | US | disclosed |
| US-7956082-B2 | Indole derivative having PGD2 receptor antagonist activity | SHIONOGI & CO., LTD (JP) | 2011-06-07 | — | — | US | disclosed |
| US-20110028717-A1 | AZAINDOLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | KUGIMIYA AKIRA | 2011-02-03 | — | — | US | disclosed |
| US-7842692-B2 | Azaindole derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2010-11-30 | — | — | US | disclosed |
| US-20090197881-A1 | Azaindole Derivative Having PGD2 Receptor Antagonistic Activity | SHIONOGI & CO., LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090105274-A1 | Indolecarboxylic Acid Derivative Having PGD2 Receptor Antagonistic Activity | SHIONOGI & CO., LTD. (JP) | 2009-04-23 | — | — | US | disclosed |
| US-20090030014-A1 | Indole Derivative Having Pgd2 Receptor Antagonist Activity | SHIONOGI & CO., LTD. (JP) | 2009-01-29 | — | — | US | disclosed |
| US-20080269295-A1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | GRUNENTHAL GMBH (DE) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212549-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | FIBP, FN1, TPX2 | CHRNA7 3579/4885SIGMAR1 3597/4885CYP2D6 4011/4885 |
| US-20110028717-A1 | AZAINDOLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | PTGDR, HRH2, PTGDR2 | CHRNA7 473/4885SIGMAR1 177/4885CYP2D6 414/4885 |
| US-20090105274-A1 | Indolecarboxylic Acid Derivative Having PGD2 Receptor Antagonistic Activity | PTGDR, CYSLTR1, CNR1 | CHRNA7 661/4885SIGMAR1 85/4885CYP2D6 512/4885 |
| US-20090197881-A1 | Azaindole Derivative Having PGD2 Receptor Antagonistic Activity | PTGDR, HRH2, PTGDR2 | CHRNA7 480/4885SIGMAR1 146/4885CYP2D6 367/4885 |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | CHRNA7 3309/4885SIGMAR1 3709/4885CYP2D6 3211/4885 |
| US-20080269295-A1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | TPMT, ABCB1, FDPS | CHRNA7 4540/4885SIGMAR1 1739/4885CYP2D6 10/4885 |
| US-11897874-B2 | Compounds and methods for modulating Interleukin-2-inducible T-cell kinase | IL2, NFATC1, IL2RA | CHRNA7 4600/4885SIGMAR1 4301/4885CYP2D6 4530/4885 |
| US-20120142687-A1 | INDOLECARBOXYLIC ACID DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | PTGDR, CYSLTR1, CYSLTR2 | CHRNA7 748/4885SIGMAR1 132/4885CYP2D6 498/4885 |
| US-20090030014-A1 | Indole Derivative Having Pgd2 Receptor Antagonist Activity | HRH2, PTGDR, CNR2 | CHRNA7 640/4885SIGMAR1 146/4885CYP2D6 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.